Quality System
Lixin Honor:

Lixin Pharmaceutical was approved by U.S. Food and Drug Administration (FDA) in 2010, and had a review with zero defect in 2015.

Lixin Pharmaceutical was approved by European Directorate for the Quality of Medicines (EDQM), European Medicines Agency (EMA) in Oct, 2016.

A number of products receive certificates of GMP by China Food and Drug Administration (NMPA)

About Us
Since established in 2000, Suzhou Lixin Pharmaceutical CO., Ltd. has been aimed at develop the global normative dominant market of APIs and advanced intermediates, driven by technological innovation, taken the path of sustainable development, and gradually form a raw materials products system including anti-tumor, cardiovascular, anti-platelet and treatment of senile dementia and other areas. Lixin Pharmaceutical has already been the high-quality supplier of many global pharmaceutical companies, and also established long-term relationship with a number of well-known domestic and foreign pharmaceutical companies to achieve win-win cooperation.
  • GMP Products

    GMP Products Clopidogrel Sulfate Idebenone Hydrochlorothiazine Indapamide Dacarbazine Ritodrine Hydrochloride Fasudil Hydrochloride Oxaliplatin

  • CEP Products

    CEP Products Hydrochlorothiazine Indapamide Dacarbazine

  • GMP Products

    GMP Products Nilotinib Hydrochloride Pemetrexed Disodium Hydrochlorothiazine Clopidogrel Sulfate Idebenone Bortezomib Gefitinib Temozolomide Ticagrelor Indapamide

  • GMP In Progress

    Pemetrexed Disodium Tenofovir Disoproxil Fumarate Capecitabine Bortezomib Gefitinib Erlotinib Hydrochloride Ticagrelor Temozolomide

  • Pharmaceutical Intermediates

  • Customization production

    Lixin Pharmaceutical has built a highly qualified R&D team and has built completely furnished professional laboratories and workshops. We can provide full range of services to clients both domestic and oversea, including R&D, quality research, registration, and customized production etc.

  • NEWS    LiXin News



    苏州龙8娱乐平台龙8国际唯一官网有限公司抗肿瘤及心血管龙8娱乐平台技改项目 自查评估报告公示

    苏州龙8娱乐平台龙8国际唯一官网有限公司抗肿瘤及心血管龙8娱乐平台技改项目 自查评估报告…...